SEC EDGAR · company profile · free

JOHNSON & JOHNSON due diligence

Who JOHNSON & JOHNSON (JNJ) is on the public record: identity, annual results, what it filed in the last year and why, straight from SEC EDGAR.

1004 filings in EDGAR's recent index, 488 of them Form 4 insider filings · view the filings on SEC EDGAR · source: SEC EDGAR submissions index and XBRL financial data

At a glance

JOHNSON & JOHNSON (JNJ) is a large accelerated filer incorporated in New Jersey, classified under SIC 2834 (Pharmaceutical Preparations), and lists on NYSE. Its fiscal year ends January 3. It has also filed as JOHNSON & JOHNSON ET AL.

For the fiscal year ended December 28, 2025, its 10-K reported revenue of $94.2B, up 6.0% from the year before, net income of $26.8B, and total assets of $199B.

In the twelve months to October 9, 2026 it made 118 filings on EDGAR, including 1 annual report, 3 quarterly reports, 8 current reports on Form 8-K, and 65 Form 4 insider filings. Its 8-Ks were filed most often for results of operations (4), Regulation FD disclosures (2), and other events (2).

CIK
0000200406
Filer status
Large accelerated filer
Industry (SIC)
Pharmaceutical Preparations (2834)
Incorporated
New Jersey
Listed on
NYSE
Tickers
JNJ
Fiscal year end
01-03

Annual results

Fiscal year endedRevenueNet incomeTotal assets
2025-12-28$94.2B +6.0%$26.8B +90.6%$199B
2024-12-29$88.8B +4.3%$14.1B -60.0%$180B
2023-12-31$85.2B$35.2B$168B
As reported in each 10-K's XBRL data on SEC EDGAR (revenue tag RevenueFromContractWithCustomerExcludingAssessedTax); a later 10-K's restatement replaces the earlier figure.
FilingFiledPeriodAccession
Annual report (10-K)2026-02-112025-12-280000200406-26-000016
Quarterly report (10-Q)2026-07-232026-06-280000200406-26-000153
Current report (8-K)2026-08-042026-08-040000200406-26-000167

Filing activity

118 filings since 2025-10-09. By form:

4
65
144
18
8-K
8
SCHEDULE 13G/A
5
13F-HR
4
10-Q
3
11-K
2
13F-HR/A
2

8-K items in the last 12 months: results of operations (Item 2.02, 4) · Regulation FD disclosures (Item 7.01, 2) · other events (Item 8.01, 2) · officer or director changes (Item 5.02, 1) · shareholder vote results (Item 5.07, 1).

FiledFormDocumentPeriod
2026-09-104FORM 42026-09-08
2026-09-104FORM 42026-09-08
2026-09-104FORM 42026-09-08
2026-09-044FORM 42026-09-02
2026-09-02144Form 144 notice of proposed sale
2026-09-013FORM 32026-09-01
2026-08-184FORM 42026-08-17
2026-08-17144Form 144 notice of proposed sale
2026-08-144FORM 42026-08-13
2026-08-13144Form 144 notice of proposed sale
free alert

Free. One email a day at most, only when something changes. Confirm by email first; unsubscribe with one click. Privacy.

The full due-diligence dossier on JOHNSON & JOHNSON

The free view above is identity and filing dates. The paid dossier reads the filings: business and segments, financial trend, insider and institutional activity, litigation and risk-factor themes, recent news, and the red flags, every claim cited and delivered with a data appendix.

agents: POST /v1/dossier with {"ticker":"JNJ"} over x402 or MPP, $0.85

Sample output and API docs · all reports

JNJ insider filingsAll company profiles13F fund holdingsAll reports

Generated from public SEC EDGAR filings. Filing data is shown as filed. This is information, not investment advice.